Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) Director Joseph L. Goldstein unloaded 2,000 shares of the stock on the open market in a transaction dated Thursday, August 14th. The stock was sold at an average price of $347.65, for a total value of $695,300.00. Following the completion of the sale, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $2,085,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on REGN. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $345.94.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.36% on Thursday, hitting $347.74. The stock had a trading volume of 566,565 shares. Regeneron Pharmaceuticals has a 1-year low of $227.64 and a 1-year high of $352.49. The stock’s 50-day moving average is $312.5 and its 200-day moving average is $307.7. The company has a market cap of $34.910 billion and a price-to-earnings ratio of 97.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.08 EPS for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.